The SWI/SNF family of chromatin-remodelling complexes, also known as BRG1/BRM-associated factor (BAF) complexes (BOX 1), are key regulators of nucleosome positioning. The SWI/SNF family chromatin remodeling complexes are multi-subunit, ATP-dependent molecular machines that slide and evict nucleosomes. They play a major role in control of the chromatin structure and regulate gene transcription in eukaryotic cells. Mutations of the human complexes are often found in cancers and neurodevelopmental disorders. Mammalian SWI/SNF complexes belong to three broad subfamilies: canonical BAF (cBAF); polybromo-associated BAF (PBAF); and the GLTSCR1 or GLTSCR1L-containing and BRD9-containing (GBAF) complex. All three complexes contain the core subunits including SMARCC1, SMARCC2, and either of the ATPases SMARCA4 or SMARCA2, but also contain numerous variable subunits that provide each of the complexes with a distinct identity.
The human SWI/SNF complexes are frequently mutated in cancer. Loss of the peripheral subunits, such as SMARCB1, PBRM1, and SMARCE1, results in formation of defective complexes, which delocalize on chromatin, deregulate gene transcription, and potentially are oncogenic. Cancer genome-sequencing studies have revealed a remarkably high prevalence of mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes, with nearly 25% of all cancers harbouring aberrations in one or more of these genes. Consequently, increasing research interest is being focused on understanding the prognostic and, in particular, the potential therapeutic implications of mutations in genes encoding SWI/SNF subunits[1][2].
FHD-909 (LY4050784) 是一种具有口服活性的选择性 SMARCA2 (BRM) ATP 酶抑制剂,可强效抑制纯化的 BRM ATP 酶(IC50 为 0.0025 μM),其对 BRM 的选择性比对纯化的 SMARCA4 (BRG1) ATP 酶高 35.69 倍,并能诱导合成致死效应、抑制细胞增殖、调控靶基因表达,在 SMARCA4 突变型癌细胞及异种移植模型中实现显著的肿瘤生长抑制与消退,可用于 SMARCA4/BRG1 突变型癌症、晚期实体瘤及 BAF 复合物相关疾病的研究。
SMARCA2 Ligand-Linker Conjugate-4 是一种靶蛋白配体-连接子偶联物 (Target Protein Ligand-Linker Conjugate),包含 SMARCA2 配体 和可募集 E3 连接酶的 PROTAC 连接子,可用于合成 PROTAC SMARCA2 degrader-35 (MS-J46911)。
SMARCA2-IN-7(compound 12)是 BRM 和 BRG1 的双抑制剂(IC50 均小于 0.005),具有抗肿瘤增殖作用,可抑制 BRG1 缺失的 SKMEL5 肿瘤增殖,其在 SKMEL5 中的细胞增殖活力 AAC50 为 13 nM,在 H1299 细胞中抑制 KRT880 的细胞增殖活力 AAC50 为 42 nM。
SMARCA2-IN-6 是一种对 SMARCA2 和 SMARCA4 的 IC50 值均 <0.005 μM 的 SMARCA2/SMARCA4 抑制剂,对 BRG1 突变型黑色素瘤具有抗癌活性,可用于 Brg1/Smarca4 突变癌症的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号